#Blueprint registry full#

I started studying Finance because I always wanted to do Finance. Then I went to college at University of Washington at Seattle. Then my dad moved and got a job at Boeing, so I moved to Seattle. Growing up, I remember my mom teaching English to some of the Saudi princes. I grew up in an American compound in Riyadh and had an amazing childhood. Nevin Shetty: I was born in Alabama but the first memory I have is of Saudi Arabia. Where are you from? Where were you born, raised, and in what kind of background? Sramana Mitra: Let’s start at the very beginning of your journey. With Blueprint, we show you the same strategy as executed by Nevin Shetty to get into TechStars. In a previous story, we showed you how Jas Grewal bootstrapped his company CareSkore with a paycheck and then got into YCombinator with a validated business. Southeast Georgia Health System - Physician AssociatesĬontact: Gwen Gratto-Cox Investigator: Antonio Moran, Jr.If you haven’t already, please study our Bootstrapping Course and Investor Introductions page. Principal Investigator: Trevor Feinstein, MDĮmory University - Winship Cancer InstituteĬontact: Alicia Escobar Investigator: Cathy Graham, MD Winter Haven, Florida, United States, 33881Ĭontact: Jan Bauer, RN Investigator: Kamal Sharma, DOĬontact: Keisa Mansfield Cancer Institute Sylvester Comprehensive Cancer Center - University of MiamiĬontact: Teresa Torres Investigator: Reshma L Mahtani, MDĬontact: Deborah Schmitt Investigator: Pavan Kancharla, MDĬontact: Jennifer Boyd Investigator: Robert Gabordi, MDĬontact: Khattiya Chharath Investigator: Charles Cox, MD

Jacksonville, Florida, United States, 32256Ĭontact: Tabetha Gayton Investigator: Pooja Advani, MDĬontact: Rebecca Delph Investigator: Madhavi Venigalla, MD Jacksonville, Florida, United States, 32224Ĭontact: Tarra Ullig Investigator: Shahla Masood, MD Principal Investigator: Jennifer Crozier, MD Jacksonville, Florida, United States, 32207 Medical Oncology and Hematology ConsultantsĬontact: Julie Yucis Investigator: Jamal Misleh, MDĬontact: Chris Lawton Investigator: June Lee, MDĬontact: Tonnica Sasanas, RN, BSN 56 Investigator: June Lee, MDīoca Raton, Florida, United States, 33428Ĭontact: Maggie Szymczak Investigator: Jane Skelton, MDĬlearwater, Florida, United States, 33756Ĭontact: Debra Ellis, RN 72 Investigator: Peter Blumencranz, MDĭaytona Beach, Florida, United States, 32114Ĭontact: Deborah Reynolds Investigator: Ruby Anne Deveras, MD Waterbury, Connecticut, United States, 06706Ĭontact: Jessica Bello Investigator: Beth Sieling, MD Van Nuys, California, United States, 91405Ĭontact: James Dunham Investigator: Thomas Lomis, MDĬontact: Wafa El-Ejmi Investigator: Sami Diab, MDĬontact: Joseph Ruybal, MA Investigator: Julie Barone, MDĬontact: Paige Bordelon Investigator: Julie Barone, DO Principal Investigator: Laura Esserman, MD San Francisco, California, United States, 94158Ĭontact: Katherine Leggat-Barr Investigator: Rita Mukhtar, MD Redding, California, United States, 96001 Palm Springs, California, United States, 92262Ĭontact: Claudia Fortiche Investigator: Laura Lee, MD

#Blueprint registry full#

Generate hypotheses for targeted subset analyses and trials based on full genome dataįLEX is an observational (phase IV) study.īirmingham, Alabama, United States, 35243Ĭontact: Lisa Clemons Investigator: Jennifer De Los Santos, MDĬontact: Julie Klinker Investigator: Rachel Swart, MDĬomprehensive Cancer Center at Desert Regional Medical Center.Utilize shared registry infrastructure to examine smaller groups of interest.Create a large scale, population-based registry of full genome expression data and clinical data to investigate new gene associations with prognostic and/or predictive value.Treatment is at the discretion of the physician adhering to NCCN approved regimens of a recognized alternative.Ĭlinical data will be collected and entered online at the time points listed: patient enrollment, time of treatment, 1 year post-treatment, and 3, 5, and 10 years post diagnosis. Approximately 25,000 patients from 125+ US based institutions will be enrolled.

Study arm appendices will specify treatment arm, inclusion criteria, and number of patients needed. The FLEX Registry will include all patients with stage I-III breast cancer who have received MammaPrint and BluePrint testing in any clinical setting. Why Should I Register and Submit Results?.